Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Unresectable Colorectal Cancer 1Pancreatic Neoplasms 1Hodgkin Disease 1

Interventions

Nivolumab 10Doxorubicin 10Cyclophosphamide 10Vinblastine 9Radiotherapy 8Dacarbazine 8Brentuximab Vedotin 8Bleomycin 7fludarabine phosphate 6fludarabine 6Prednisone 6Etoposide 6pembrolizumab 5Melphalan 5Whole-Body Irradiation 4Vincristine 4Mycophenolic Acid 4Filgrastim 4Tacrolimus 3Radiation 3Prednisolone 3Peripheral Blood Stem Cell Transplantation 3Granulocyte Colony-Stimulating Factor 3Busulfan 3Thiotepa 2Sirolimus 2Procarbazine 2Mechlorethamine 2Bendamustine Hydrochloride 2tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Hodgkin Disease × magrolimab × Clear all
NCT04788043 2025-04-02

Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

Stanford University

Phase 2 Active not recruiting
8 enrolled
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡